Progress in the development of antiviral therapy for HTLV-III-associated diseases.
Yarchoan
R
R
Broder
S
S
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy*; D000965:Antimony / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D017245:Foscarnet; D006678:HIV / Q000187:drug effects; D006801:Humans; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use; D017828:Rifabutin; D012294:Rifamycins / Q000627:therapeutic use; D013498:Suramin / Q000627:therapeutic use; D013936:Thymidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D014414:Tungsten / Q000627:therapeutic use; D017973:Tungsten Compounds; D015215:Zidovudine
D000998:Antiviral Agents; D012294:Rifamycins; D017973:Tungsten Compounds; D017828:Rifabutin; D017245:Foscarnet; D012254:Ribavirin; D015215:Zidovudine; C009613:ammonium tungsten antimonate hydroxide oxide; D013498:Suramin; D000965:Antimony; D010746:Phosphonoacetic Acid; D014414:Tungsten; D013936:Thymidine